Massion P B, Frans A
Cliniques Universitaires Saint-Luc, Département de Médecine Interne, Bruxelles, Belgique.
Rev Pneumol Clin. 1992;48(2):49-57.
Inhalation of the platelet activating factor (PAF) produces symptoms of bronchial asthma, a disease in which PAF plays an important role. This lipid mediator released by many kinds of cells exerts its effects on blood cells and on cells of the bronchial wall both directly and indirectly. The crucial role played by PAF in the inflammatory cascades explains the current interest in specific PAF antagonists. These antagonists have both bronchodilator and anti-inflammatory properties and act simultaneously as beta-adrenoceptor agonists and corticosteroids. The first clinical trials of PAF antagonists in the treatment of resistant asthma have given results that are interesting but not superior to those obtained with the conventional anti-asthmatic drugs. The indications for PAF antagonists combined with other specific antagonists will soon be determined.
吸入血小板活化因子(PAF)会引发支气管哮喘症状,PAF在该疾病中起重要作用。这种由多种细胞释放的脂质介质直接或间接作用于血细胞和支气管壁细胞。PAF在炎症级联反应中发挥的关键作用解释了目前对特定PAF拮抗剂的关注。这些拮抗剂具有支气管扩张和抗炎特性,同时起到β肾上腺素能受体激动剂和皮质类固醇的作用。PAF拮抗剂治疗难治性哮喘的首批临床试验结果令人感兴趣,但并不优于传统抗哮喘药物。PAF拮抗剂与其他特定拮抗剂联合使用的适应证很快将得到确定。